Clinical Trials


Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

The recruitment status of this study is unknown.

Verified July 2002

Merck Sharp & Dohme Corp.

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: January 17, 2000
Last updated: June 23, 2005
Last Verified: July 2002
History of Changes


The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy. This study will look at the effectiveness of this drug combination and side effects.

Condition Intervention Phase
HIV Infections

Drug : Indinavir sulfate
Drug : Ritonavir
Drug : Lamivudine
Drug : Stavudine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Activity of Indinavir Sulfate 1200 Mg q.d. and Ritonavir 200 Mg q.d. in Combination With Stavudine and Lamivudine in Treatment Naive HIV-1 Infected Patients

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 8

Detailed Description:

Patients entering this study initiate antiretroviral therapy. For 24 weeks patients receive daily dosages of IDV, RTV, 3TC, and d4T. Patients are seen at Day 1 and at Weeks 2, 4, 8, 12, 16, 20, and 24 for physical examinations, pregnancy testing, and blood sampling to monitor CD4 count and viral load. On Day 14, blood is drawn frequently for 24 hours for IDV and RTV pharmacokinetic sampling. The incidence of serious and drug-related adverse events and of adverse events leading to study discontinuation is tabulated.



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Are at least 18 years old.
  • Have a viral load of 5,000 copies/ml or greater.
  • Have a CD4 count of at least 50 cells/mm3.

  • Exclusion Criteria
    Patients will not be eligible for this study if they:
  • Have taken any antiretroviral (anti-HIV) agent.
  • Are pregnant.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002451


United States, Florida
Univ of Miami School of Medicine
Miami, Florida, United States, 33136
United States, New York
Albany Med College
Albany, New York, United States, 12208
SUNY at Stony Brook / Division of Infectious Diseases
Stony Brook, New York, United States, 11794

Sponsors and Collaborators

Merck Sharp & Dohme Corp.
More Information

More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00002451   History of Changes  
Other Study ID Numbers: 246U  
Study First Received: January 17, 2000  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Drug Therapy, Combination
HIV Protease Inhibitors
CD4 Lymphocyte Count
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load

Additional relevant MeSH terms:
HIV Infections
Stavudine processed this data on July 20, 2018
This information is provided by